ANALYSIS: Orphan disease specialists find a likely home in Big Pharma
This article was originally published in Scrip
Executive Summary
Tumbling over the patent cliff, many big pharma companies are being forced to find new strategies for sustaining sales growth, wherever possible minimising the risk of generic competition.